US$ 29.50
leading brands of glp-1 agonists in biopharma Top 20 biopharmas' market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots GLP-1 Receptor Agonist Companies and
Description
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-beta peptide-induced impairment of spatial learning and memory in rats
2033 (USD BILLION) FIGURE 14 GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS

(2020) 69:89LB

Studies show that people who stop taking the medication may regain the weight theyve lost
-agonists-market-key-insight.png)
-2.6/2.7 kg), respectively (7274)
